Drugs Made In America Acquisition Corp.(DMAA)— Stock Profile, AI Score & Financials

Financials · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Drugs Made In America Acquisition Corp. (DMAA) stock profile, AI quality score, and SEC EDGAR financial data, a Financials sector company. DMAA is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of DMAA by reported 13-F value include MIZUHO SECURITIES USA, Karpus Management, Polar Asset Management Partners, based on the most recent SEC filings. DMAA trades on the Nasdaq exchange and files with the SEC under CIK 2028614. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DMAA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Drugs Made In America Acquisition Corp. directly from SEC EDGAR.